Up to now, only 13 ERCC3 truncating and splicing mutations have been reported in a minimum of 29 breast cancer patients and confer a 1.53 ∼ 3.54-fold breast cancer risk [9–12, 24, 30, 31, 33, 36, 37]. This evidence concerns the gene ERCC3 and breast carcinoma.